Why Akari Therapeutics Stock Price Rallied Today

Akari Therapeutics Stock Rallied

Autoimmune and inflammatory disease treatments are works in progress with some approved products demonstrating remarkable efficacy. Still there are untreated inflammatory diseases, among them are those where the complement (C5) and/or leukotriene (LTB4) systems are implicated.

Akari Therapeutics (AKTX) is a small biopharmaceutical company focused on therapeutics for the orphan autoimmune and inflammatory diseases.The Company announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its product nomacopan for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients. 

Leave a Reply